Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6935 related articles for article (PubMed ID: 27223332)

  • 1. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
    Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
    Li D; Li M; Li H; Shi P; Chen M; Yang T
    Dis Markers; 2023; 2023():5272125. PubMed ID: 37077340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
    PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
    Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
    Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
    Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D;
    Ann Oncol; 2016 Mar; 27(3):417-23. PubMed ID: 26646759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
    Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
    Haaland B; Tan PS; de Castro G; Lopes G
    J Thorac Oncol; 2014 Jun; 9(6):805-11. PubMed ID: 24787964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 347.